Why Pharma's Next AI Challenge Is Supervision, Not Adoption

As pharmaceutical companies move AI into patient access and support operations, most still rely on manual sampling and general performance metrics to judge whether those systems are working. Amy Brown, founder and CEO of Authenticx and a former healthcare executive, argues that the industry's harder challenge is no longer deploying the technology, but supervising it. In this Q&A, Brown discusses why regulated patient interactions demand continuous, healthcare-specific evaluation, how clinical and regulatory judgment becomes explicit evaluation criteria, and what AI monitoring AI looks like in practice.